SUGAR LAND--February 26, 2015--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--While the entire life science sector, including the pharmaceuticals, biotech and medical device industries, continues its healthy capex investment in North America, there has been a noticeable uptick in Western European activity. Even with global industry reporting at the limited beta level, a quick search of the Industrial Info Pharmaceutical-Biotech Database reveals 10 active projects valued at more than $2.5 billion.

Within this article: Details on key projects from major companies, such as Bristol-Myers Squibb (NYSE:BMS), Jacobs Engineering Group (NYSE:JEC), Novartis AG (NYSE:NVS) and AstraZeneca plc (NYSE:AZN).